Vertex Pharmaceuticals Market capitalization 2024

Vertex Pharmaceuticals Market capitalization

108.89 B USD

Vertex Pharmaceuticals Dividend yield

Ticker

VRTX

ISIN

US92532F1003

WKN

882807

In 2024, Vertex Pharmaceuticals's market cap stood at 108.89 B USD, a 27.34% increase from the 85.51 B USD market cap in the previous year.

The Vertex Pharmaceuticals Market capitalization history

YEARREVENUE (undefined USD)GROSS MARGIN (%)NET INCOME (undefined USD)
2029e16.1953,186.34
2028e14.9757,515.92
2027e13.8362,235.65
2026e13.1565,485.38
2025e11.9572,024.82
2024e10.9378,764.41
20239.8787,213.62
20228.9387,903.32
20217.5788,062.34
20206.2188,142.71
20194.1686,841.18
20183.0586,562.1
20172.4989,040.26
20161.787,85-0.11
20151.0388,66-0.56
20140.5893,16-0.74
20131.2192,66-0.45
20121.5384,50-0.11
20111.4195,490.03
20100.14100,00-0.75
20090.1100,00-0.64
20080.184904,27-0.46
20070.24325,13-0.39
20060.223977,36-0.21
20050.165349,29-0.2
20040.18380,72-0.17

Vertex Pharmaceuticals Aktienanalyse

What does Vertex Pharmaceuticals do?

Vertex Pharmaceuticals Inc is a biopharmaceutical company that focuses on researching, developing, and marketing therapies for rare diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts, USA. Since its inception, Vertex has been dedicated to pushing the boundaries of science to develop groundbreaking therapies for diseases such as cystic fibrosis and other rare genetic disorders. The company's history began in 1989 when Joshua Boger, a former employee of Merck & Co., founded the company with the goal of becoming a leading developer of therapies for rare diseases. In 1993, Vertex went public, achieving significant success. In 2012, the company announced the development of the first approved therapy for the treatment of cystic fibrosis, Kalydeco. Since then, Vertex has expanded its technology and production capabilities and continues to work on developing additional therapies for rare genetic disorders. The business model of Vertex Pharmaceuticals Inc is based on researching and developing therapies for rare genetic disorders. The company collaborates closely with patients, leading scientists, and medical professionals to develop groundbreaking therapies. Vertex is a vertically integrated company, handling everything from research and development to production and marketing in-house. This allows the company to maintain control over the entire development and production process to ensure the highest quality products. Vertex is divided into different divisions to organize its activities. The Paris research facility specializes in the development of therapies for cystic fibrosis and other rare genetic disorders. The San Diego facility focuses on the development of treatments for cancer. Additionally, the company maintains research facilities in the UK and Canada. Vertex Pharmaceuticals Inc's most well-known product is Kalydeco, the first approved medication for the treatment of cystic fibrosis targeting a specific genetic mutation. Kalydeco aims to restore the function of a specific protein in the lungs, targeting the underlying cause of the disease. The company has also developed other therapies for cystic fibrosis, including Orkambi and Symdeko, which also target genetic mutations. Vertex also has therapies for cancer in its portfolio, such as the drug VX-970 currently in clinical trials for cancer treatment. In summary, Vertex Pharmaceuticals Inc is a leading biopharmaceutical company focused on developing therapies for rare genetic disorders. Since its founding in 1989, Vertex has continuously improved its technology and production capabilities, becoming one of the most innovative companies in the industry. The company is vertically integrated and consists of various research facilities dedicated to developing therapies for different diseases. Vertex has developed several groundbreaking medications for genetic disorders, including Kalydeco (the first approved medication for cystic fibrosis), Orkambi, and Symdeko. Vertex Pharmaceuticals Inc is an example of how research and development can play a significant role in treating rare diseases. Vertex Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Vertex Pharmaceuticals revenue by segment

In the annual report of the Vertex Pharmaceuticals share (US92532F1003, 882807, VRTX), it breaks down its revenues into 4 segments: 1. Symdeko, 2. Orkambi, 3. Kalydeco, 4. Trikafta. The Vertex Pharmaceuticals stock (WKN: 882807, ISIN: US92532F1003, Ticker Symbol: VRTX) is a leading investment for investors interested in participating in the Health Care sector.

Market capitalization Details

Exploring Vertex Pharmaceuticals's Market Capitalization

Vertex Pharmaceuticals's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Vertex Pharmaceuticals's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Vertex Pharmaceuticals's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Vertex Pharmaceuticals’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Vertex Pharmaceuticals Stock

What is the current Vertex Pharmaceuticals market capitalization?

The current market capitalization of Vertex Pharmaceuticals is 108.89 B USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Vertex Pharmaceuticals.

How has the market capitalization of Vertex Pharmaceuticals developed in recent years?

The market capitalization of Vertex Pharmaceuticals has increased/decreased by 27.34% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Vertex Pharmaceuticals?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Vertex Pharmaceuticals?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Vertex Pharmaceuticals have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Vertex Pharmaceuticals pay?

Over the past 12 months, Vertex Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vertex Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Vertex Pharmaceuticals?

The current dividend yield of Vertex Pharmaceuticals is .

When does Vertex Pharmaceuticals pay dividends?

Vertex Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vertex Pharmaceuticals?

Vertex Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Vertex Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vertex Pharmaceuticals located?

Vertex Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vertex Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vertex Pharmaceuticals from 3/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/29/2024.

When did Vertex Pharmaceuticals pay the last dividend?

The last dividend was paid out on 3/29/2024.

What was the dividend of Vertex Pharmaceuticals in the year 2023?

In the year 2023, Vertex Pharmaceuticals distributed 0 USD as dividends.

In which currency does Vertex Pharmaceuticals pay out the dividend?

The dividends of Vertex Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Vertex Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank

Andere Kennzahlen von Vertex Pharmaceuticals

Our stock analysis for Vertex Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vertex Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.